Abstract
The results of 3 clinical trials of a new antiinflammatory/analgesic substance (4-isobutylphenylacetic acid: Ibufenac) in patients with rheumatoid arthritis are presented and discussed. It is concluded that Ibufenac is a useful drug in the treatment of the symptoms of rheumatoid arthritis. It appears to be as effective as aspirin in this respect at the dosage levels employed and its use was associated with considerably fewer side effects.